Advanced Hemostatic Systems for Enhanced Bleeding Control

Publication ID: 24-11857564_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Advanced Hemostatic Systems for Enhanced Bleeding Control,” Published Technical Disclosure No. 24-11857564_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857564_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,564.

Summary of the Inventive Concept

The invention integrates anion exchanger-based hemostatic compositions with cutting-edge technologies like AI, IoT, blockchain, and nanomaterials to create a new generation of hemostatic systems with improved efficacy, real-time monitoring, and enhanced delivery.

Background and Problem Solved

The original patent disclosed hemostatic compositions comprising an anion exchanger and calcium salt. However, these compositions had limitations in terms of real-time monitoring, controlled release, and bleeding risk prediction. The new inventive concept addresses these limitations by combining the patented composition with distinct technologies to create a more powerful and efficient system.

Detailed Description of the Inventive Concept

The inventive concept comprises a wearable device with a sensor for detecting bleeding and a dispenser for administering the hemostatic composition. The system utilizes machine learning algorithms to predict bleeding risk and optimize composition delivery. Additionally, the composition can be enhanced with nanomaterials for controlled release and improved efficacy. The system can be integrated with a blockchain-based tracking system for secure monitoring and data management.

Novelty and Inventive Step

The new claims introduce the synergistic combination of anion exchanger-based hemostatic compositions with AI, IoT, blockchain, and nanomaterials, which provides a new and non-obvious solution for bleeding control. The integration of these technologies enables real-time monitoring, controlled release, and bleeding risk prediction, making the system more effective and efficient than the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different AI algorithms, various IoT sensors, or distinct nanomaterials. The system could also be adapted for use in different medical settings, such as emergency response or surgical procedures.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the medical device and pharmaceutical industries, particularly in the areas of emergency response, surgical hemostasis, and wound care. The system's ability to provide real-time monitoring and controlled release could revolutionize the field of bleeding control, offering a new standard of care for patients.

Field of Art

Medical devices and hemostatic technologies, specifically focusing on compositions and systems for controlling bleeding, with expertise in materials science, biomedical engineering, and medical device design

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in biomedical engineering or chemical engineering, experienced in developing medical technologies, familiar with hemostatic materials, sensor technologies, and emerging medical device integration strategies

Obviousness Rationale

A PHOSITA would recognize that integrating modern technologies like AI, IoT, and nanomaterials with existing hemostatic compositions represents a predictable extension of known medical device innovation strategies. The source patent's fundamental hemostatic composition provides a clear technical foundation for technological enhancement. The proposed variations represent logical combinations of known techniques in medical monitoring and drug delivery systems.

Obvious Combinations & Variations

Source Patent Element
Hemostatic composition with anion exchanger and calcium salt
PTD Variation
Adding nanomaterials for controlled release of hemostatic composition
Obviousness Reasoning
Nanomaterial drug delivery is a well-established technique for improving pharmaceutical absorption and controlled release, making this combination a predictable optimization for a PHOSITA
Source Patent Element
Hemostatic composition in slurry or liquid form
PTD Variation
Integrating composition with IoT-enabled wearable sensor and dispensing system
Obviousness Reasoning
Automated drug delivery and monitoring systems are common in medical technology, representing an obvious technological progression for improving hemostatic treatment efficacy
Source Patent Element
Composition devoid of blood clotting proteins
PTD Variation
Implementing machine learning algorithms for bleeding risk prediction
Obviousness Reasoning
Predictive medical technologies using AI are increasingly standard, and applying machine learning to existing medical compositions represents a straightforward technological enhancement
Source Patent Element
Hemostatic composition with specific ion exchange matrix
PTD Variation
Blockchain-based tracking system for monitoring hemostatic intervention
Obviousness Reasoning
Secure medical data tracking is a known technological trend, and integrating blockchain with medical device technologies represents an obvious extension of existing data management practices
Source Patent Element
Composition with cross-linked matrix
PTD Variation
Wearable device with real-time bleeding detection and automated composition delivery
Obviousness Reasoning
Automated medical intervention systems are well-established, and applying such technologies to hemostatic treatments represents a predictable technological progression
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857564 and the published technical disclosure, a person having ordinary skill in the art would find the proposed hemostatic system variations obvious, as they represent predictable combinations of known medical device technologies with established hemostatic composition principles. The disclosed innovations constitute obvious extensions of prior art, rendering subsequent claims covering similar technological integrations unpatentable under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,564
TitleHemostatic composition comprising an anion exchanger and a calcium salt
Assignee(s)Omrix Biopharmaceuticals Ltd.